Tag Archives: healthcare

Pediatrics Plus Partners with Leavitt Equity Partners for Next Phase of Growth

Fulcrum

Leavitt Equity Partners and Fulcrum Equity Partners Partner to Advance Pediatrics Plus’s Mission of Empowering Children and Families Through Specialized Care

CONWAY, Ark.–(BUSINESS WIRE)–Leavitt Equity Partners—a healthcare-focused private equity fund founded by former U.S. Secretary of Health and Human Services, Mike Leavitt—is proud to announce its partnership with Pediatrics Plus, a leading pediatric therapy provider based in Conway, Arkansas. In collaboration with Leavitt Equity Partners, Fulcrum Equity Partners—an operations-driven growth equity fund specializing in healthcare and B2B technology—and Western Governors University—an additional strategic partner—join the investor group to support Pediatrics Plus’s continued growth and mission.

“Pediatrics Plus has a remarkable track record of providing exceptional care and achieving outstanding outcomes for children and their families”

Post this

Pediatrics Plus offers a range of services including physical therapy, occupational therapy, speech and language pathology, and applied behavior analysis (ABA) therapy. Pediatrics Plus has grown to now providing specialized healthcare services to more than 6,000 children with special needs and developmental delays each year.

“This partnership represents an exciting milestone in our journey,” said Scott Street, CEO of Pediatrics Plus. “Our mission has always been to provide exceptional care for children with developmental needs, and with the expertise and support of Leavitt Equity Partners and Fulcrum Equity Partners, we are well-positioned to expand into new markets and enhance our service offerings for the families we serve.”

The incumbent management team has established a robust operational foundation and an innovative service delivery model, positioning Pediatrics Plus for efficient scaling. With the combined healthcare and operational expertise of Leavitt Equity Partners, Fulcrum Equity Partners, and Western Governors University (including its investment arm, Juvo Ventures), Pediatrics Plus is well-equipped to embark on its next phase of growth, expand its impact on children and families, and address the critical supply shortage in the pediatric therapy industry.

“Pediatrics Plus has a remarkable track record of providing exceptional care and achieving outstanding outcomes for children and their families,” said Andrew Clark, Managing Partner at Leavitt Equity Partners. “We are honored to partner with their team and help them scale their mission to reach even more children and families in need.”

“Pediatrics Plus embodies the entrepreneurial spirit and commitment to excellence that we seek in our partners,” added Chad Hooker, Principal at Fulcrum Equity Partners. “We are excited to collaborate and build on their success, helping them unlock new opportunities for growth and innovation.”

Pediatrics Plus founders, Todd and Amy Denton, will continue forward as the largest shareholders of Pediatrics Plus and will both continue to serve on the Board of Directors. “We are delighted to partner with Leavitt Equity Partners and Fulcrum Equity Partners to continue to advance the mission of high-quality pediatric therapy within current and new markets,” said Amy Denton. “We believe this new partnership will accelerate the Company’s growth and opportunities to serve more families and we are excited for this next chapter for Pediatrics Plus.”

Stephens Inc. acted as exclusive financial advisor and Bass Berry & Sims PLC acted as legal advisor to Pediatrics Plus.

Dorsey & Whitney LLP acted as legal advisor to Leavitt Equity Partners.

McDermott Will & Emery acted as legal advisor to Fulcrum Equity Partners.

About Pediatrics Plus

Pediatrics Plus is a specialized pediatric healthcare provider that utilizes a unique and innovative blended service model designed to deliver the best outcomes for children. Operating with a progressive mindset, the organization consistently seeks and discovers more effective ways to achieve greater results for its clients. With growing experience, Pediatrics Plus has continually challenged itself to think outside the box, adding diverse services and delivery models to overcome obstacles that might prevent children from accessing or benefiting from the care they need. Learn more at https://www.pediatricsplus.com/

About Leavitt Equity Partners

Leavitt Equity Partners is a value-add, healthcare focused private equity firm. Founded in 2014 by Michael Leavitt, former United States Secretary of the Department of Health and Human Services, LEP leverages the healthcare intelligence and broad network of its Principals to help portfolio companies thrive in a complex and ever-changing healthcare system.

LEP manages over $400 million in capital, raised primarily from strategic healthcare partners including healthcare provider systems, national and regional health insurers, healthcare service providers, healthcare IT companies, pharmaceutical companies, and healthcare executives and entrepreneurs. Learn more at http://www.leavittequity.com.

About Fulcrum Equity Partners

Fulcrum Equity Partners is an Atlanta-based growth equity firm that gives entrepreneurs the capital and hands-on support they need to take their companies further, faster. Fulcrum invests in healthcare services and B2B tech executives searching for $5 million to $30 million of equity in minority and majority growth opportunities. Fulcrum’s partners believe in building businesses the right way, meeting teams where they are, and helping them imagine a bigger and brighter future by building the right systems, processes, teams, and culture. All of that starts with the right experience, the right support, and the right relationship. Learn more at http://www.fulcrumep.com.

About Western Governors University

Western Governors University (WGU) is a nonprofit, online university driven by a mission to expand access to education and opportunity. Founded by a bipartisan group of U.S. governors in 1997, WGU is committed to reinventing higher education by putting students at the center of learning. Through its competency-based approach, WGU enables students to progress at their own pace, measuring success through mastery of skills rather than time spent in class. With a focus on affordability, flexibility, and workforce relevance, WGU serves over 150,000 students across the nation and has awarded more than 400,000 degrees in fields such as healthcare, business, education, and IT. Learn more at www.wgu.edu.

Contacts

Media Contact:
Stormy Goeckeritz
Leavitt Equity Partners
801-879-2340
Stormy.Goeckeritz@leavittequity.com

Categories: News

Tags:

Suvoda and Greenphire to Merge Creating a Technology Platform Optimizing Clinical Trial Processes and Streamlining the Patient Journey

BainCapital

CONSHOHOCKEN, PA and KING OF PRUSSIA, PA – January 13, 2025 – Suvoda, a global clinical trial technology company specializing in randomization and trial supply management, consent, and patient outcomes data collection solutions for complex, life-sustaining studies, and Greenphire, a leader in clinical trial payments, financial management and patient support tools, have agreed to merge. The merger will unite two complementary clinical trial technology leaders with a shared passion and proven history of creating a more seamless clinical trial experience for patients, sites, and sponsors.

Bringing together Suvoda’s and Greenphire’s trusted, market-leading offerings will create a powerful end-to-end platform to support the patient journey in clinical trials and help bring medicines to those who need them most. Further, the comprehensive product portfolio will deliver patient-centric solutions, including randomization and trial supply management, eConsent, eCOA, patient and grant payments, study budgeting, and travel and logistics all within a unified digital experience. The merger will enhance patient access and engagement in clinical trials, simplify site access to essential technologies, and position pharma and contract research organization (CRO) partners to more easily achieve their clinical trial objectives.

Jagath Wanninayake, Suvoda’s founder and CEO, will serve as Chief Executive Officer for the combined company following closing which is expected in Q2 2025 following the receipt of required regulatory approvals. Greenphire CEO Jim Murphy will continue to lead Greenphire through closing and will serve as an advisor to the company throughout 2025 ensuring a smooth transition. The leadership team will consist of individuals from both companies. Thoma Bravo, a leading software investment firm, will be the lead strategic investor in the combined company, and Bain Capital Tech Opportunities will make a significant minority investment into the combined company upon the closing of the transaction.

William Blair LLC is serving as financial advisor and Morgan Lewis is serving as legal advisor for Suvoda. J.P. Morgan Securities LLC is serving as financial advisor and Goodwin Procter is serving as legal advisor to Greenphire.

Supporting Quotes:
“Suvoda and Greenphire are both mission-driven businesses, focused on easing sponsor, site, and patient burden in clinical trials. Combined, we’ll continue to deliver with the same excellence and service our customers expect, while accelerating the pace of product innovation in the most urgent moments of the most urgent trials. I am excited for Suvoda and Greenphire to join forces – we each serve a great portion of the patient journey and have a shared mission to transform patients’ and sites’ experiences within clinical trials. Now, we’ll do it together.” – Jagath Wanninayake, Chief Executive Officer, Suvoda

“The transaction marks the beginning of an incredible new journey for Greenphire, our customers, partners and employees. The merger will enable us to even better serve all clinical trial stakeholders as we work with our new colleagues to redefine the site and patient experience.  By putting these two industry leaders together, our organization will be able to offer you the unprecedented ability to partner with one singular solution provider – from eConsent, randomization, and eCOA to budgets, payments, travel, and mobile access.” – Jim Murphy, CEO, Greenphire

“The combination of Suvoda and Greenphire, two leaders in clinical trial technology, will create a new company with significant scale, a unique set of complementary product offerings, and a highly skilled management team with an impressive track record of success and history of high growth. We look forward to supporting the go-forward company’s next phase of growth.” – Hudson Smith, Partner, Thoma Bravo

“Clinical trials are increasingly complex and pharmaceutical companies are turning to trusted technology partners like Suvoda and Greenphire to serve mission-critical roles throughout the trial. We are thrilled that these two complementary industry leaders are coming together to simplify the clinical trial workflow and provide a more seamless user experience for patients, sites, and sponsors.” – Peter Hernandez, Senior Vice President, Thoma Bravo

“We are excited to back the combination of Suvoda and Greenphire. Both businesses stand out in terms of best-in-class customer feedback, which stems from their modern, easy to use products and relentless focus on customer and patient outcomes. Together, the combined business will be able to invest in the most innovative platform for clinical trial operations, resulting in continued success for all participants in the clinical trial ecosystem.” – Michael Grandfield, Managing Director, Bain Capital Tech Opportunities.

###

About Suvoda
Suvoda is a global clinical trial technology company specializing in complex, life-sustaining studies in therapeutic areas like oncology, central nervous system (CNS), and rare diseases. Founded in 2013 by experts in eClinical technologies, Suvoda empowers clinical trial professionals to manage the most urgent moments in the most urgent trials through advanced software solutions delivered on a single platform. Headquartered outside Philadelphia, Suvoda also maintains offices in Portland, OR, Barcelona, Spain, Bucharest and Iasi, Romania, and Tokyo, Japan. The company’s Net Promoter Score (NPS) consistently exceeds the technology industry average, contributing to the company being selected by trial sponsors and CROs to support more than 1,500 trials across 85 countries. To learn more, visit suvoda.com. Follow Suvoda on LinkedIn.

About Greenphire 
Greenphire is the pioneer in financial management and patient support for global clinical trials. From participant reimbursements, travel, and engagement to study budgeting and data, site payments, and more, the company connects the dots across disparate processes and stakeholders to get studies done faster. Founded in 2008 and guided by a dedication to site and participant experience, Greenphire’s best in class solutions accommodate regional workflow preferences, navigate challenging regulatory demands, and address the unique needs of every patient. Greenphire currently supports more than one million active trial participants and more than 25,000 investigative research teams at sites in 80 countries worldwide.  Greenphire Means GO. To learn more, we invite you to visit greenphire.com and follow us on LinkedIn.

Categories: News

Tags:

Novo Holdings co-leads €32 million Series A for Coave Therapeutics to advance pipeline of next-generation genetic medicines

Novo Holdings

Coave Therapeutics (‘Coave’), a biotechnology company focused on developing genetic medicines, today announced its €32 million ($33 million) Series A financing. The financing was co-led by Novo Holdings A/S and Bpifrance, with participation from Invus and UI Investissement, alongside existing investors Seroba Life Sciences, Fund+, Kurma Partners, Omnes Capital and Turenne Capital.

The financing will enable Coave to advance its proprietary ALIGATER™ (Advanced Vectors-Ligand Conjugates) platform, a breakthrough technology addressing key limitations in the delivery of genetic payloads to extra-hepatic tissues, including limited tissue specificity, delivery efficiency and safety.

ALIGATER™ enables conjugation of targeting ligands, such as small molecules, peptides, or antibody fragments, on AAV or non-viral vectors, offering superior delivery efficiency, tissue specificity and safety profile for a broad range of diseases.

The platform streamlines the manufacturing process by avoiding prior AAV capsid modifications. These capabilities could enable Coave to develop best-in-class genetic medicines designed for specific indications.

Further, the funding enables Coave to advance its lead pre-clinical assets towards clinical development, with a primary focus on the central nervous system (CNS), neuromuscular and eye diseases. Coave plans to advance two development candidates to CTA/IND-enabling studies in 2026.

“We are delighted to welcome this group of top-tier investors who share our vision for the ALIGATER™ platform. This funding is a critical milestone for Coave as we work to develop a new generation of targeted, safer, and more efficacious genetic medicines,” said Rodolphe Clerval, CEO of Coave. “It also reinforces our ability to expand collaborations with pharma and biotech partners, driving innovation in the field of genetic medicines for a broad range of diseases.”

Emmanuelle Coutanceau, Partner at Seed Investments, Novo Holdings, commented: “Coave’s unique technology platform, strong proof-of-concept data, and experienced team, position it at the forefront in the development of new generations of genetic medicines. Further, we are pleased to see Coave leveraging the strength of the Novo Holdings life science network by acquiring one of our early-stage companies operating in stealth mode. We are excited to announce this significant step in expanding Coave’s global footprint, with Denmark serving as a stepping stone in its international growth.”

“Coave, with its ALIGATER™ platform for creating a new class of targeted genetic medicines, has the potential to deliver groundbreaking new treatments to patients in need,” said Jean-François Morin, Investment Director at Bpifrance – InnoBio Funds. “With this Series A financing and a top-tier team, Coave will be able to progress its pipeline of internal programs.”

In connection to the financing, Emmanuelle Coutanceau and Jean Francois Morin will join Coave’s Board of Directors.

About Coave Therapeutics
Coave Therapeutics is a genetic medicine company pioneering the development of innovative solutions to enhance the precision, safety, efficacy and manufacturability of genetic medicines. With its proprietary ALIGATER™ platform, Coave is at the forefront of addressing challenges in gene therapy delivery to extra-hepatic tissues, creating a robust pipeline targeting CNS, neuromuscular and eye diseases.

Headquartered in Paris, France, Coave Therapeutics is backed by leading international life sciences investors. For more information about the science, pipeline, and people, please visit coavetx.com and follow us on LinkedIn.

About Bpifrance and InnoBio funds
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurance. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export). InnoBio funds are investment funds dedicated to the life sciences, managed by Bpifrance, which is also one of the LPs alongside pharmaceutical companies and institutional investors. These funds aim to invest in companies developing innovative products, close to or in early clinical development, with the objective of bringing them to clinical proof of concept. InnoBio funds take minority equity stake in companies and can lead or co-lead the investment rounds. For more information, please visit: www.bpifrance.com

Further information

Novo Holdings
Marie-Louise Jersin, Senior Lead, Public Relations
maj@novo.dk

 

Coave Therapeutics 
Rodolphe Clerval, CEO
contact@coavetx.com

Categories: News

Tags:

FIRE1 Secures $120 Million Financing to Revolutionize Heart Failure Care

GIMV

FDA awards Breakthrough Device Designation to Fire1’s Norm™ system

DUBLIN – Strictly embargoed to 08.00 hours GMT/Dublin time Jan. 7, 2025

FIRE1, a leading connected medical device solutions company, today announced the successful completion of a $120 million financing round to accelerate the company’s mission to transform the lives of millions of people living with heart failure.

FIRE1’s Norm™ heart failure management system offers a groundbreaking approach for patients to manage heart failure. By enabling patients to engage in physician directed self-management, Norm reduces the burden on healthcare staff, making it easier to keep patients healthier and at home. The funding will enable the company to complete a pivotal clinical trial of the Norm™ system.

The round was led by Polaris Partners and Elevage Medical Technologies, joined by new investors Sands Capital and Longitude Capital, and existing investors Andera Partners, Gilde Healthcare, Gimv, the Ireland Strategic Investment Fund, Lightstone Ventures, Medtronic, NEA (New Enterprise Associates), Novo Holdings, and Seventure Partners.

Categories: News

Tags:

Mashura Announces $300M Strategic Partnership with Warburg Pincus

Warburg Pincus logo

Partnership to fuel growth, innovation and expand client reach in veterinary and dental markets

January 7th, 2025 — Scottsdale, AZ – Mashura, a leading inventory intelligence platform in healthcare, today announced a $300 million strategic partnership with a newly formed financing vehicle sponsored by Warburg Pincus, the pioneer of private equity growth investing. Mashura will focus on expanding its customer base across the U.S. and globally, innovating key solutions and increasing integration partnerships.

Mashura, a global leader in inventory intelligence solutions, provides cutting-edge smart cabinet technology to veterinary and dental clinics, which drives hard dollar cost savings by streamlining operations, improving inventory management and ensuring seamless compliance with DEA and state regulatory audits. Operating through two specialized brands, CUBEX, serving the veterinary industry, and Zimbis, catering to the dental sector, Mashura delivers tailored solutions designed to meet the unique needs of each market. The company’s software platform offers real-time reporting and intuitive analytics, empowering customers to prioritize operational demands and optimize inventory supply. By reducing medication costs and improving efficiency, Mashura supports clinics in driving positive EBITDA. With installations in over 16 countries worldwide, Mashura’s solutions are transforming how healthcare providers manage their inventory and improve patient outcomes.

“One of my core focuses is to foster a culture at Mashura that emphasizes serving one another, developing innovative solutions, and creating programs that enhance healthcare for both people and their pets. Through our best-in-class solutions, we help healthcare companies maximize profitability, control inventory, and optimize workflow efficiencies, thereby increasing safety and mitigating risk,” said Anton Visser, CEO, Mashura. “This partnership unlocks an exciting new opportunity for Mashura, allowing us to innovate, expand and drive continued success. The support from Warburg Pincus is invaluable and we look forward to leveraging their decades-long experience in healthcare and financing strategies.”

“Mashura is a valued part of the vet and dental markets with their innovative storage cabinets, helping clients with increased billing capture, reduced inventory, consolidated analytics, automated suggested ordering and regulatory audits – all important services for healthcare providers,” said José Arredondo, Principal, Warburg Pincus. “We are excited to partner with Anton and the CUBEX and Zimbis teams on this next phase of growth, expanding the reach and services for the company to benefit customers as the demand for automation solutions continues to accelerate,” added Jordan Jones, Principal, Warburg Pincus.

The equity for the transaction is being provided by Warburg Pincus Capital Solutions Founders Fund (“WPCS FF”), which closed in September 2024 with over $4 billion in commitments. Mitsubishi Corporation remains a strategic partner to Mashura.

About Mashura

Mashura is a leading provider of innovative health care automation and cloud-based business intelligence solutions that enable veterinary and dental facilities to improve medication care, cost and patient outcomes, while at the same time increasing regulatory compliance. Mashura is headquartered in Scottsdale, Arizona, home to its corporate office and distribution center. More information can be found at www.mashura.com.

About Warburg Pincus

Warburg Pincus LLC is the pioneer of private equity global growth investing. A private partnership since 1966, the firm has the flexibility and experience to focus on helping investors and management teams achieve enduring success across market cycles. Today, the firm has more than $86 billion in assets under management, and more than 230 companies in their active portfolio, diversified across stages, sectors, and geographies. Warburg Pincus has invested in more than 1,000 companies across its private equity, real estate, and capital solutions strategies.

Warburg Pincus funds have invested over $18 billion in more than 180 innovative healthcare companies around the world, including Summit Health/CityMD, Modernizing Medicine, Ensemble Healthcare Partners, and Bausch + Lomb. The firm also has a successful track record of investing in capital solutions related transactions historically. The Warburg Pincus Capital Solutions Founders Fund consists of investments that include DriveCentric, Excelitas, MB2, MIAX, Nord Security, Service Compression, and United Trust Bank.

The firm is headquartered in New York with offices in Amsterdam, Beijing, Berlin, Hong Kong, Houston, London, Luxembourg, Mumbai, Mauritius, San Francisco, São Paulo, Shanghai, and Singapore. For more information, please visit www.warburgpincus.com or follow us on LinkedIn.

Contact

Warburg Pincus

Sarah Bloom, Associate Director, Communications

Sarah.bloom@warburgpincus.com

Mashura

Neels Visser, Director of Marketing

nvisser@mashura.com

Categories: News

Tags:

Novo Holdings Participates in €90 Million Series A Financing Round for Orbis Medicines to Support Development of Oral Macrocycle Drugs

Novo Holdings
  • Financing to support the development of Orbis’ pipeline of next-generation macrocycles, nCycles, with an initial focus on validated blockbuster biologic targets
  • Orbis’ nGen platform systematically explores oral macrocycle design with automated chemistry and machine learning
  • Novo Holdings Partner, Morten Graugaard, to lead Orbis as CEO

COPENHAGEN – January 6, 2025 – Novo Holdings today announced its participation in a €90 million Series A financing for Orbis Medicines. The round was led by New Enterprise Associates (NEA), with participation from new investors including Eli Lilly and Company, Cormorant, the Export and Investment Fund of Denmark, alongside existing investors Novo Holdings and Forbion. Morten Graugaard, Partner at Novo Holdings, has been appointed the Chief Executive Officer of Orbis Medicines following nearly three years serving as Executive Chair of its Board of Directors.

Orbis was founded in 2021 by the Seed Investments team of Novo Holdings to pioneer a new era for oral macrocycle drug discovery and build on the ground-breaking science developed by Professor Christian Heinis and Sevan Habeshian at the Swiss Federal Institute of Technology in Lausanne (EPFL). João Ribas, Principal, Novo Holdings, and Morten Graugaard provided highly collaborative operational management and strategic guidance, exemplifying the team’s active, hands-on approach to venture creation.

Macrocycles are a large and diverse family of compounds with highly desirable therapeutic properties. However, developing these compounds as oral drugs has historically been a significant challenge. Orbis is focused on using its leading nGen platform to generate high-value oral alternatives to blockbuster biologic drugs and targets to maximize value for patients.

“The benefits of an oral format include dose control, convenience, ease of dosing, and feasibility for much larger populations of patients. Orbis is leveraging macrocycles to unlock these benefits in major areas validated by existing biologics, and we are proud to have played an integral role in shaping the company from its earliest stages,” said João Ribas, Principal, Novo Holdings. “The combination of automated chemical synthesis, high-throughput assays, and machine learning ignited our enthusiasm and drove us to start collaborating to build Orbis before its first financing round. We congratulate Morten on his appointment and the team on their successes to-date and look forward to advancing the future of macrocycles.”

About Orbis Medicines
Orbis Medicines is pioneering a new era for oral macrocycle drug discovery. Its nGen platform systematically delivers macrocycle candidates, termed nCycles. These are optimized for oral bioavailability, which has historically hindered therapeutic development of this versatile class of molecules. Orbis’ pipeline is initially focused on nCycle candidates against targets validated by blockbuster biologic drugs delivered by injection. In 2024, Orbis raised a EUR 26 million series seed round co-led by Novo Holdings and Forbion. Proof-of-concept of Orbis’ work has been published in Nature Communications and Nature Chemical Biology. The company is located in Copenhagen, Denmark and Lausanne, Switzerland. For more information, please visit: www.orbismedicines.com.

About Novo Holdings A/S
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion. www.novoholdings.dk

Further information

Christian Mostrup
Head of Public Relations
+ 45 306 74805
cims@novo.dk

Categories: News

Tags:

Hologic Completes Acquisition of Gynesonics, Inc

MARLBOROUGH, Mass.–(BUSINESS WIRE)– Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused on the development of minimally invasive solutions for women’s health, for approximately $350 million.

“We are excited to complete the acquisition of Gynesonics and to increase access to their Sonata® System, which complements and expands our range of minimally invasive solutions for heavy periods and fibroids,” said Brandon Schnittker, President of Surgical Solutions at Hologic. “As global champions for women’s health, we are dedicated to empowering surgeons with diverse, cutting-edge treatment options as we strive to transform women’s lives for the better.”

The Sonata System is a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. The technology combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure.

“As we embark on this new phase with Hologic, we are excited to see the continued success of the Sonata System, which has already made a difference in the lives of thousands of women,” said Skip Baldino, President and Chief Executive Officer of Gynesonics. “Hologic’s commitment to women’s health and their leadership in innovation make them a perfect fit for our organization.”

About Hologic

Hologic, Inc. is a global leader in women’s health, dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. For more information on Hologic, visit www.hologic.com and connect with us on LinkedIn, Facebook, X (Twitter), Instagram and YouTube.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about Hologic’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; strategies, positioning, resources, capabilities and expectations for future performance; and financial outlook and other guidance. These forward-looking statements are based upon assumptions made as of this date and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.

Risks and uncertainties that could adversely affect Hologic’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the possibility that the anticipated benefits from the transaction or products cannot be fully realized or may take longer to realize than expected; the possibility that costs or difficulties related to the integration of Gynesonics’ operations with those of Hologic will be greater than expected; the coverage and reimbursement decisions of third-party payers and the guidelines, recommendations, and studies published by various organizations relating to the use of products and treatments; the ability to successfully manage ongoing organizational and strategic changes, including Hologic’s ability to attract, motivate and retain key employees; the development of new competitive technologies and products; regulatory approvals and clearances for products; the anticipated development of markets in which products are sold into and the success of products in these markets; the anticipated performance and benefits of products; estimated asset and liability values; anticipated trends relating to Hologic’s financial condition or results of operations; and Hologic’s capital resources and the adequacy thereof.

The risks included above are not exhaustive. Other factors that could adversely affect Hologic’s business and prospects are described in Hologic’s filings with the SEC. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

Hologic, The Science of Sure, Gynesonics and Sonata are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Source: Hologic, Inc.

Media Contact
Bridget Perry
Senior Director, Corporate Communications
(+1) 508.263.8654
bridget.perry@hologic.com

Investor Contact
Michael Watts
Corporate Vice President, Investor Relations
(+1) 858.410.8514
michael.watts@hologic.com
Source: Hologic, Inc.

Categories: News

Tags:

Remodel Health Raises More Than $100 Million to Continue Expansion in ICHRA Market

Oak HC FT

Remodel Health, the #1 Individual Coverage Health Reimbursement Arrangement (ICHRA) provider for brokers, today announced it has raised more than $100 million from Oak HC/FT and Hercules Capital, Inc. (NYSE: HTGC) in growth funding.

Remodel offers an end-to-end, white-labeled tech platform that supports employers and employees with everything they need tolaunch and access their ICHRA plans, including plan creation andadministration, call center support, automated quoting, employee onboarding, HRIS integrations and payments with carriers and access to ancillary products. Starting with the group to individual health insurance shift in 2015, Remodel has become a dominant player in the ICHRA space, bolstered by the acquisition of PeopleKeep in early 2024. Together, the two companies are uniquely positioned to serve small, medium and large employers, with a suite of products across ICHRA and QSEHRA. With this investment from Oak HC/FT and Hercules Capital, Remodel will look to continue its national expansion.

Remodel stands apart from the competitive set with its meaningful scale and a go-to-market motion defined by its white-glove service, deep broker relationships and easy-to-understand approach to marketing and sales. Importantly, as employer health insurance premiums continue to increase, ICHRA provides Remodel’s customers with predictable annual benefits costs, driving stability and an average of 30% savings for the office of the CFO. Over the past 12 months, Remodel has focused more on partnering with insurance brokers and agencies tosupport its ICHRA expansion across the U.S. As a result, the Remodel business grew 11x YoY in broker-led ICHRA bookings and this will be a key area of growthand expansion for the business moving forward.

“We are on a mission to resource organizations with missions that matter, partnering with employers and their brokers to do so. Remodel Co-Founders Justin Clements and Scott Lingle and I started trailblazingin 2015, and PeopleKeep founder Paul Zane Pilzer identified this shift likepension to 401(k) in the early 2000’s,” said Austin Lehman, CEO of Remodel Health. “We are now seeing it begin to come to fruition. The Oak team have been great dreamers with us and have great connections in the insurance payer space to accelerate growth and help increase access to medical care and resource organizations with missions that matter.”

ICHRA was created in 2020 as a flexible alternative to traditional group health insurance, offering choices around contribution levels to employers and more personalized options around benefits for employees. Similar to a 401K, employers of any size can provide an allowance of pre-taxdollars to their employees. This is used by employees for the purchase of someor all of their healthcare premiums for insurance bought on the ACA exchanges. It offers an exciting cost-savings proposition for employers, particularly small and mid-size ones, who want to offer health insurance to their teams, by allowing them to move their employees to state risk pools to help offset costs, instead of trying to level-fund or self-insure.

“We have been looking at the ICHRA space for a few years now, waiting for a stand out company with the combination of hyper-scaling potential, an ambitious go-to-market strategy and focused dedication from the leadership team,” said Andrew Adams, Co-Founder and Managing Partner, Oak HC/FT. “We are honored that the Remodel team chose to partner with us and cannot wait to support them in their efforts to build out the ICHRA market for employers and brokers across the U.S.”

Since its launch, the ICHRA market has been steadily increasing and is projected to 10X by 2032.According to the HRA Council, ICHRAadoption increased 29% from 2023 to 2024, with Applicable Large Employersgrowing at the highest rate – of 84%. Remodel’s approach to distribution and plan partnership best positions them to take advantage of this growth, now and in the future.

About Remodel Health

Remodel Health isthe expert guide for employers and brokers navigating the complexities oftransitioning to ICHRA. With nearly a decade of experience in the individualhealth benefits space, our proprietary software and licensed health benefits experts deliver tailored solutions for businesses with 100 to 10,000 employees. Committed to best-in-class customer service, we provide hands-on support throughout the process, ensuring successful implementation and long-term success. Learn more about how we transform health benefits at remodelhealth.com.

About PeopleKeep

PeopleKeep specializes in helping small and midsize businesses offer affordable, flexible health benefits through the ICHRA and qualified small employer HRA (QSEHRA). By focusing on expanding access to coverage for employees often overlooked by traditional employer-sponsored plans due to cost and complexity, PeopleKeep empowers small employers to thrive. With easy-to-use software, automated compliance, and a seamless employee experience, PeopleKeep is committed tosimplifying benefits administration and making health coverage more accessible.

About Oak HC/FT

Oak HC/FT is a venture and growth equity firmspecializing in investments in fintech and healthcare. Using partnership as afoundation, Oak HC/FT guides companies and founders at every stage, from seedto growth, to create businesses that make a measurable and lasting impact.Founded in 2014, Oak HC/FT has invested in over 85 portfolio companies and hasover $5.3 billion in assets under management. Oak HC/FT is headquartered inStamford, CT, with an office in San Francisco, CA. Follow Oak HC/FT on LinkedIn and X and learn more at https://www.oakhcft.com/.

About Hercules Capital, Inc.

Hercules Capital, Inc. (NYSE: HTGC) is the leading and largest specialty finance company focused on providing senior secured venturegrowth loans to high-growth, innovative venture capital-backed companies in abroad variety of technology and life sciences industries. Since inception (December 2003), Hercules has committed more than $21 billion to over 660companies and is the lender of choice for entrepreneurs and venture capitalfirms seeking growth capital financing. Companies interested in learning moreabout financing opportunities should contact info@htgc.com.

Categories: News

Tags:

Eurobio Scientific: EB Development obtains a significant majority of the capital with 88.9% held at the end of the Reopened Offer to continue its development with NextStage AM and IK Partners

IK Partners

Paris, 19 December 2024

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible) and EB Development announce the final outcome of the takeover bid initiated by EB Development (the “Offer“), based on the results published on 18 December by the Autorité des marchés financiers (AMF) at the end of the reopening period of the Offer (the “Reopened Offer“).

644,911 ordinary shares were tendered to the Reopened Offer, which closed on 17 December 2024. These are in addition to the 4,582,971 ordinary shares tendered to the Initial Offer, giving a total of 5,227,882 ordinary shares tendered to the Offer, enabling EB Development, acting in conjunction with funds managed by NextStage AM and IK Partners, and Mr. Denis Fortier, Chairman and CEO, and other members of the Board of Directors and senior management of the Company ,[1] to hold, after assimilation of the treasury shares held by Eurobio Scientific (the “Company“), 9,113,592 shares representing 88.92% of the share capital and voting rights of the Company.

As the percentage of share capital and voting rights attained following the Reopened Offer is below the 90% threshold allowing the implementation of a squeeze-out procedure, the additional price of €1.25 per share will not be paid. Settlement and delivery will take place on 23 December 2024.

Denis Fortier, Chairman and CEO of Eurobio Scientific, said: “The results of the takeover bid give Eurobio Scientific the means to accelerate its development with the support of NextStage and now IK Partners, active shareholders who share our strategy and have a good knowledge of our in vitro diagnostics and intelligent health markets. We would like to thank our shareholders for their confidence and support in making this transaction a success.”

NextStage AM acquired a stake in Eurobio Scientific on 18 May 2022 through the creation of a joint holding company with the entrepreneurs called “EurobioNext”. NextStage AM invested in the company through the “Pépites et Territoires” programme by AXA France & NextStage AM and its NextStage EverGreen vehicle.  NextStage AM has supported Eurobio Scientific in structuring its management team and accelerating its external growth strategy, in particular, through significant M&A transactions (including the acquisition of the Dutch company GenDx, one of the world leaders in HLA typing for transplant compatibility, in August 2022).[2]

NextStage AM and IK Partners, as core shareholders, will continue to support the group’s team of entrepreneurs in this new stage of the Company’s growth.

Grégoire Sentilhes, Chairman and co-founder of NextStage AM, commented: “Since May 2022, the team of entrepreneurs led by Denis Fortier has accelerated the transformation of the group post-Covid, in particular through the acquisition of GenDx, by strengthening the part of its business dedicated to proprietary products. We are delighted to be pursuing the development of Eurobio Scientific, which has the potential to become a leading SME in its market, alongside IK Partners, a leading investor who shares our vision and entrepreneurial values.”

Rémi Buttiaux, Managing Partner at IK Partners, added: “Eurobio Scientific has established itself as a market leader in the field of in vitro diagnostics and we are looking forward to working closely with the management team, NextStage AM and other stakeholders to support this next phase of development for the business.”

Warning:

This press release has been prepared for information purposes only. It does not constitute an offer to purchase or exchange or the solicitation of an offer to sell or exchange any securities of Eurobio Scientific S.A. or an offer to purchase or exchange or the solicitation of an offer to sell or exchange any securities of Eurobio Scientific S.A. The release, publication or distribution of this press release may be restricted by law in certain jurisdictions and, accordingly, persons in possession of this press release in such jurisdictions should inform themselves of and observe any applicable legal restrictions. Investors and shareholders in France are strongly advised to read the Offer documents referred to in this announcement as they contain important information about the proposed transaction and other related matters. EB Development’s offer document and “other information” document are available on the websites of the AMF (www.amf-france.org) and Eurobio Scientific S.A. (www.eurobio-scientific.com) and may be obtained free of charge on request from EB Development (43, avenue de Friedland, 75008 Paris, Crédit Industriel et Commercial (6, avenue de Provence, 75009 Paris) and Degroof Petercam Wealth Management (44, rue de Lisbonne, 75008 Paris). Eurobio Scientific’s note in response and “other information” document are available on the AMF (www.amf-france.org) and Eurobio Scientific S.A. (www.eurobio-scientific.com) websites and may be obtained free of charge on request from Eurobio Scientific S.A. (7, avenue de Scandinavie, ZA de Courtaboeuf, 91953 Les Ulis). Neither Eurobio Scientific S.A., EB Development, nor their respective shareholders, advisers or representatives accept any liability whatsoever in connection with the use by any person of this press release or its contents, or more generally in connection with this press release.

[1] Denis Fortier (Chairman and Chief Executive Officer), Cathie Marsais (Chief Operating Officer), Olivier Bosc (Chief Operating Officer), Jean-Michel Carle-Grandmougin (Chief Operating Officer and member of the Board of Directors) and Hervé Duchesne de Lamotte (member of the Board of Directors).

[2] https://nextstage-am.com/eurobio-scientific-participation-de-nextstage-am-annonce-la-signature-dun-accord-en-vue-dacquerir-gendx-leader-mondial-du-diagnostic-hla-aux-pays-bas/

For further questions, please contact:

Eurobio Scientific Group
Denis Fortier, Chairman and CEO
Olivier Bosc, Managing Director / CFO
Tel. +33 1 69 79 64 80

Calyptus
Mathieu Calleux
Investor Relations
Tel. +33 1 53 65 68 68
eurobio-scientific@calyptus.net

NextStage AM
Ghita Farage – gf@nextstage.com – +33 6 10 50 32 56

Shan
Laurence Tovi – laurence.tovi@shan.fr – +33 6 20 58 29 02 / Lola Gozlan – lola.gozlan@shan.fr – +33 6 24 76 83 40 / Clara Flore – clara.flore@shan.fr – +33 6 16 04 64 33

IK Partners
Vidya Verlkumar – vidya.verlkumar@ikpartners.com – +44 (0) 7787 558 193

About Eurobio Scientific

Eurobio Scientific is a major player in the field of speciality in vitro diagnostics. It is involved in the research and marketing of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and offers dedicated reagents to research laboratories, including pharmaceutical and biotechnology companies. With its many partnerships and strong hospital presence, Eurobio Scientific has its own extensive distribution network and a portfolio of proprietary products. The Group has around 320 employees, four production units based in the Paris region, Germany, the Netherlands and the United States, and subsidiaries in Milan (Italy), Dorking (UK), Sissach (Switzerland), Bünde (Germany), Antwerp (Belgium) and Utrecht (Netherlands).

For more information, visit www.eurobio-scientific.com

Eurobio Scientific shares are listed on Euronext Growth Paris.
Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.mnemonic: ALERS – ISIN Code: FR0013240934 – Reuters: ALERS.PA – Bloomberg: ALERS:FP

Read More

About EB Development

EB Development is the initiator of the Offer and intends to bring together in its capital, directly or indirectly, funds managed by IK Partners and Eurobio Scientific’s reference shareholders, including Nextstage and the Company’s managers and directors.

Read More

About NextStage AM

NextStage AM is an independent asset management company based in Paris and approved by the AMF. Since its inception in 2002, NextStage AM has cultivated an “entrepreneur-investor” philosophy and is one of the pioneers and specialists in innovative and patient growth capital in France. NextStage AM has developed, step by step, a multi-strategy private equity platform which, in terms of assets under management and advised, represents more than €8.7 billion as at 30 September 2024, both directly and indirectly. NextStage AM invests in a limited number of French and European innovative and growth SMEs and ETIs (81 companies in the portfolio on 30/09/2024), to which it provides entrepreneurial investor expertise and strong operational support to ensure their successful transformation. NextStage AM provides long-term support to SMEs and SMIs involved in intelligent healthcare, environmental and energy innovation and digital transformation. It provides them with the means to accelerate their development and their capacity for innovation in order to become the “Champions” of their markets, both in France and internationally, through organic and/or external growth. For more information, visit nextstage-am.com

Read More

About IK Partners

IK Partners (“IK”) is a European private equity firm focusing on investments in the Benelux, DACH, France, the Nordic countries and the UK. Since 1989, IK has raised over €17 billion of capital and invested in more than 195 European companies. IK supports companies with strong underlying potential, working in partnership with management teams and investors to create strong, well-positioned businesses with excellent long-term prospects. For more information, visit ikpartners.com

Read More

Categories: News

Tags:

Gilde Healthcare portfolio company SpliceBio Announces U.S. FDA IND Clearance of SB-007

GIlde Healthcare
December 12, 2024
Barcelona (Spain)
  • SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations
  • Phase 1/2 ASTRA study set to begin in the first half of 2025, supported by POLARIS, a pioneering company-sponsored natural history study in Stargardt disease
  • First ever IND clearance for a Protein Splicing gene therapy

SpliceBio, a genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes, today announced that the U.S. Food & Drug Administration (FDA) has cleared its investigational new drug (IND) application for lead program SB-007. SB-007 is the only clinical-stage therapeutic addressing the root genetic cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations.

Miquel Vila-Perelló, Ph.D., Chief Executive Officer, and Co-Founder of SpliceBio, said: “The FDA IND clearance of SB-007 is a significant achievement for SpliceBio and Stargardt disease patients. As the first-ever IND for a Protein Splicing gene therapy, it is a huge step forward to demonstrate the potential of this new therapeutic modality to address diseases caused by mutations in large genes such as ABCA4. SB-007 is an adeno-associated viral (AAV) vector gene therapy aimed at restoring expression of the full-length ABCA4 protein, and the only clinical-stage therapy with the potential to help all Stargardt patients. We look forward to accelerating the clinical development of SB-007, building on the Orphan Drug Designation granted by the FDA in 2024, and advancing this potentially life-changing therapeutic for patients with Stargardt disease.”

“Stargardt disease has been a challenge for the development of gene therapies due to the large size of the ABCA4 gene, and currently has no approved therapies available,” said Professor Paul Yang, M.D., Ph.D., Chief of the Paul H. Casey Ophthalmic Genetics Division at Casey Eye Institute at Oregon Health & Science University. “This new therapy utilizes a unique approach to replace the full-size, normal ABCA4 protein at high efficiency, which addresses the root cause of Stargardt disease across any pathogenic variant in the ABCA4 gene. This IND clearance represents a major milestone in the field and I am thrilled to be part of the clinical studies exploring this promising approach that could transform the lives of Stargardt disease patients.”

SpliceBio plans to initiate enrolment in the Phase 1/2 ASTRA study in the first half of 2025. ASTRA will evaluate the safety and efficacy of a single dose of SB-007 administered subretinally in patients with Stargardt disease. In March 2024, SpliceBio launched the POLARIS trial, a pioneering company-sponsored natural history study of Stargardt disease designed to evaluate disease progression, refine endpoints, and streamline eligibility criteria for accelerated enrolment into the Phase 1/2 ASTRA study. This study will enable Stargardt disease patients to benefit from more precise diagnoses, more rigorous disease monitoring, and potentially faster access to innovative therapies.

The SpliceBio Management team will be attending J.P. Morgan’s 43rd Annual Healthcare Conference 2025, being held in San Francisco from 13-16 January 2025. Please get in contact to schedule a meeting at bd@splice.bio.

About Stargardt disease
Stargardt disease is the most common form of inherited juvenile macular degeneration, affecting approximately 1 in 8,000 to 10,000 individuals. Caused by mutations in the ABCA4 gene, Stargardt disease leads to the progressive loss of central vision due to damage to the central region of the retina known as the macula. The disease is variable in the age of onset, including early onset in children and adolescents and late-onset forms in adulthood. There are no approved treatments, and patients face significant challenges in daily life as the disease progresses. Stargardt disease has remained elusive to genetic medicines due to the large size of the ABCA4 gene.

About SB-007
SB-007 is a Protein Splicing dual AAV gene therapy that delivers the full-length ABCA4 gene and aims to restore expression of the native ABCA4 protein in the retina. It has demonstrated robust pharmacological activity in animal models of Stargardt disease and durable expression and safety in non-human primates. SB-007 has been granted Orphan Drug Designation by the FDA in the US and the European Commission in Europe.

About SpliceBio
SpliceBio is a genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in large genes. The Company’s lead program, SB-007, targets the root cause of Stargardt disease, a genetic eye disease that causes blindness in children and adults. SpliceBio’s pipeline comprises additional gene therapy programs across therapeutic areas, including ophthalmology and neurology. SpliceBio’s platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein, Protein Splicing, and protein engineering research. For additional information, please visit www.splice.bio.

About Gilde Healthcare
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in therapeutics, medtech and digital health, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags: